Mark Ragosa Kiniksa Pharmaceuticals, Ltd. (KNSA) insider trading activity

Mark Ragosa is CHIEF FINANCIAL OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 22,958 shares of KNSA, which is worth approximately $500,484. The most recent transaction as insider was on Sep 02, 2024, when has been sold 956 shares (Class A Ordinary Share) at a price of $26.74 per share, resulting in proceeds of $25,563. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 23K

19.24% 3M change

46.87% 12M change

Total Value Held $500,484

Mark Ragosa Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 02 2024	SELL Payment of exercise price or tax liability	$25,563 $26.74 p/Share	956 Reduced 4.0%	22,958 Class A Ordinary Share
Sep 02 2024	BUY Exercise of conversion of derivative security	-	1,861 Added 7.22%	23,914 Class A Ordinary Share
Sep 01 2024	SELL Payment of exercise price or tax liability	$60,432 $26.74 p/Share	2,260 Reduced 9.3%	22,053 Class A Ordinary Share
Sep 01 2024	BUY Exercise of conversion of derivative security	-	4,444 Added 15.45%	24,313 Class A Ordinary Share
Jul 23 2024	SELL Open market or private sale	$601,107 $24.79 p/Share	24,248 Reduced 55.74%	19,253 Class A Ordinary Share
Jul 23 2024	BUY Exercise of conversion of derivative security	$269,152 $11.1 p/Share	24,248 Added 35.79%	43,501 Class A Ordinary Share
Apr 26 2024	SELL Payment of exercise price or tax liability	$9,100 $17.88 p/Share	509 Reduced 2.58%	19,253 Class A Common Share
Apr 26 2024	BUY Exercise of conversion of derivative security	-	991 Added 4.78%	19,762 Class A Common Share
Apr 08 2024	SELL Payment of exercise price or tax liability	$14,158 $17.9 p/Share	791 Reduced 4.04%	18,771 Class A Common Share
Apr 08 2024	BUY Exercise of conversion of derivative security	-	2,694 Added 12.1%	19,562 Class A Common Share
Apr 01 2024	SELL Payment of exercise price or tax liability	$10,125 $19.7 p/Share	514 Reduced 2.96%	16,868 Class A Common Share
Apr 01 2024	BUY Exercise of conversion of derivative security	-	1,750 Added 9.15%	17,382 Class A Common Share
Jan 03 2024	SELL Open market or private sale	$240,000 $20.0 p/Share	12,000 Reduced 43.43%	15,632 Class A Common Share
Jan 03 2024	BUY Exercise of conversion of derivative security	$105,960 $8.83 p/Share	12,000 Added 30.28%	27,632 Class A Common Share
Sep 02 2023	SELL Payment of exercise price or tax liability	$9,714 $17.76 p/Share	547 Reduced 3.38%	15,632 Class A Common Share
Sep 02 2023	BUY Exercise of conversion of derivative security	-	1,861 Added 10.32%	16,179 Class A Common Share
Sep 01 2023	SELL Payment of exercise price or tax liability	$14,048 $17.76 p/Share	791 Reduced 5.24%	14,318 Class A Common Share
Sep 01 2023	BUY Exercise of conversion of derivative security	-	2,695 Added 15.14%	15,109 Class A Common Share
Apr 26 2023	SELL Payment of exercise price or tax liability	$3,244 $11.15 p/Share	291 Reduced 2.29%	12,414 Class A Common Share
Apr 26 2023	BUY Exercise of conversion of derivative security	-	990 Added 7.23%	12,705 Class A Common Share
Apr 10 2023	SELL Payment of exercise price or tax liability	$8,471 $10.71 p/Share	791 Reduced 6.32%	11,715 Class A Common Share
Apr 10 2023	BUY Exercise of conversion of derivative security	-	2,695 Added 17.73%	12,506 Class A Common Share
Mar 20 2023	SELL Payment of exercise price or tax liability	$7,050 $11.12 p/Share	634 Reduced 6.07%	9,811 Class A Common Share
Mar 20 2023	BUY Exercise of conversion of derivative security	-	2,158 Added 17.12%	10,445 Class A Common Share
Mar 16 2023	SELL Payment of exercise price or tax liability	$2,933 $11.46 p/Share	256 Reduced 3.0%	8,287 Class A Common Share

Mark Ragosa

CHIEF FINANCIAL OFFICER

Hamilton, D0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Value

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA

Account